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The management of osteoarthritis of the shoulder in young, active patients is a challenge, and the optimal treatment has yet to be
completely established. Many of these patients wish to maintain a high level of activity, and arthroplasty may not be a practical
treatment option. It is these patients who may be excellent candidates for joint-preservation procedures in an eﬀort to avoid or
delay joint replacement. Several palliative and restorative techniques are currently optional. Joint debridement has shown good
results and a combination of arthroscopic debridement with a capsular release, humeral osteoplasty, and transcapsular axillary
nerve decompression seems promising when humeral osteophytes are present. Currently, microfracture seems the most studied
reparative treatment modality available. Other techniques, such as autologous chondrocyte implantation and osteochondral
transfers, have reportedly shown potential but are currently mainly still investigational procedures. This paper gives an overview
of the currently available joint preserving surgical techniques for glenohumeral osteoarthritis.
1.Introduction
Osteoarthritis(OA)isthemostfrequentcauseofdisabilityin
the USA [1]. It is suggested that as many as 50 million adults
suﬀer from this gradual, progressive joint failure [2]. The
prevalence of OA increases with age, typically manifesting
after the sixth decade of life, and women appear to be more
susceptible than men [2]. Though less prevalent than OA of
thekneeandhip,OAoftheshoulder(Figure 1)canbeequal-
ly debilitating [3].
Treatment of shoulder OA is typically based on the pa-
tient’s age, severity of symptoms, level of activity, radio-
graphic ﬁndings, and medical co morbidities. Nonoperative
treatment options include activity modiﬁcation, physical
therapy, oral anti-inﬂammatories, and intra-articular injec-
tions, each exhibiting varying reported eﬃcacy rates [4]. If
conservative options fail, surgical treatment should be con-
sidered.AsinotherjointsaﬀectedbysevereOA,themostde-
ﬁnitive treatment modality is joint arthroplasty. Speciﬁcally,
shoulder arthroplasty reliably results in pain reduction and
functional improvement but has been primarily studied in
older arthritic patients with lower functional demands [5–
11].
ThemanagementofshoulderOAinyoungactivepatients
remains a challenge and the optimal treatment has yet to be
completely established [12]. Many young and active patients
with early stage joint degeneration wish to maintain a high
level of activity because of recreational interests or occupa-
tional demands. In these cases, arthroplasty may not be a
practical treatment option secondary to concerns regarding
implant durability [13]. It is these patients who may be exc-
ellent candidates for joint-preservation procedures in an
eﬀort to avoid or delay joint replacement.
Glenohumeral joint preservation is not a novel concept.
Previous authors have described arthroscopic debridement
and capsular release [14–16], microfracture [17–19], correc-
tive osteotomies, osteochondral transfers, and chondral im-
plantations [20, 21] with satisfactory results. More recently
arthroscopic debridement and capsularrelease has been cou-
pledwithhumeralosteoplastyandaxillarynervedecompres-
sion in an eﬀort to improve reported outcomes [22]. These
proceduresalsotypicallyhavethebeneﬁtoflesssurgicalmor-
bidity and a quicker postoperative recovery.
The long-term outcomes of glenohumeral preservation
techniquesarepresentlyunknownbutclinicalexperiencehas2 Advances in Orthopedics
Figure 1: Arthroscopic view of severe osteoarthritis of the right
humeral head in a 53-year-old female.
shown that many patients do well with these procedures and
delay the need for prosthetic shoulder arthroplasty. Early
results from published studies do indicate that satisfactory
short-term outcomes can be expected, but these procedures
have yet to show that they can halt the arthritic progression
[14–16]. They may, however, provide a window of improved
function for this young and active population. The purpose
of this paper is to give an overview of the currently available
joint preserving surgical techniques and report on the
evidence supporting procedures available for the young and
active patient population with shoulder OA.
2. ArticularCartilage
Like other diarthrodial joints, the glenohumeral articular
surfaces are similarly covered with hyaline cartilage which on
the glenoid side is thicker at the periphery than centrally. By
contrast, the humeral articular cartilage thickness is exactly
the opposite; the cartilage thickness at the periphery is ap-
proximately 1mm, increasing from 1.2 to 1.3mm at the cen-
ter of the humeral head [23]. It is thought that this variation
in cartilage thickness may increase the congruency of the
joint’s osseous structures [24].
Theetiologyofarticularcartilageinjuryincludestrauma,
iatrogenic causes, instability, avascular necrosis, osteochon-
dritis dissecans, chemically induced, and osteoarthritis [25].
Cartilage defects rarely heal spontaneously and generally
require surgical intervention because of the poor vascular-
ization of articular cartilage and the presence of few undif-
ferentiated cell populations able to respond to degenerative
or traumatic injury [26].
Osteoarthritis aﬀects not only the articular cartilage but
also the bone and the capsule of the joint. This results in
osteophyte formation, subchondral sclerosis, and capsular
thickening. Often these manifestations are as important to
treat as the chondral damage present. Lesions of the cartilage
have been historically graded according to the Outerbridge
classiﬁcation grade I–IV [27]. In 2003, the International Car-
tilage Repair Society (ICRS) published the ICRS Hyaline
Cartilage Lesion Classiﬁcation System, a modiﬁcation of the
Outerbridge classiﬁcation, which is currently used as the in-
ternational standard [28]( Figure 2).
Focal lesions of articular cartilage of the glenohumeral
joint are often encountered during arthroscopic treatment of
other shoulder injuries [29–33]. Several authors report grade
III to IV chondral lesions in 5%–17% of patients undergo-
ing rotator cuﬀrepair [30, 31], and 6% to 29% of those being
treated for impingement symptoms [29, 32]. Unpublished
data from our clinical database conﬁrms these previous re-
ports, revealing a 12.4% prevalence of high-grade cartilage
lesions in over 2000 patients who have undergone arthrosco-
pic surgery [33]. It is critical to realize that joint preservation
techniques should not only be employed once arthrosis oc-
curs, but also as an important adjunct to other procedures in
an eﬀort to minimize damage and slow progression to ar-
thritis.
3. CurrentTreatment Options
3.1. Nonoperative Treatment. Though nonoperative man-
agement of glenohumeral OA will not ultimately alter the
progression of disease, it can be eﬀective in mitigating symp-
toms. Activity modiﬁcation is often an initial step in this
process. Although the recently published treatment guide-
lines of the American Academy of Orthopaedic Surgeons are
unable to recommend for or against physical therapy, ma-
nual therapy, or manipulation based on the available publi-
shed literature [4], these modalities are often prescribed be-
cause they represent minimal risk to the patient, and there
certainly have been anecdotal reports of success. The same
guidelines were also unable to recommend for or against the
use of intra-articular corticosteroid injections or oral phar-
macotherapy. Anecdotal experience again suggests that these
treatments are eﬀective for many patients, but often only for
a limited duration of time. Because these therapies also pose
minimal patient risk, they are often initiated prior to surgical
intervention. Randomized trials do exist indicating that
nonsteroidal anti-inﬂammatory drugs (NSAIDs) are more
eﬀective than both paracetamol and placebo for pain re-
lief of arthritic conditions [34, 35]. It is important, how-
ever, to be aware of the increased risk of gastro-intestinal
andcardiovascularsideeﬀectswhenconsideringNSAIDpre-
scription for this cause [35]. Some evidence also exists sup-
porting glenohumeral viscosupplementation for glenohu-
meral arthrosis. Silverstein et al. reported that glenohumeral
viscosupplementation resulted in a signiﬁcant improvement
in shoulder pain and function outcome scores 6 months
following injection [36].
3.2. Operative Treatment: Symptom Relief
3.2.1. Debridement with Capsular Release. Arthroscopic de-
bridement of the shoulder with glenohumeral arthrosis has
been used to treat patients with (early) OA of the shoulder.
By stabilizing cartilage lesions, eliminating mechanical sym-
ptoms, and releasing capsular contractures, satisfactory out-
comes have been obtained in small cohorts of patients asAdvances in Orthopedics 3
AB
A
A
B
B
C D
ICRS grade 0—normal
ICRS grade 1—nearly normal
Superﬁcial lesions. Soft indentation (A)
and/or superﬁcial ﬁssures and cracks (B)
ICRS grade 2—abnormal
Lesions extending down to <50% of cartilage depth
ICRS grade 3—severely abnormal
Cartilage defects extending down >50% of cartilage depth (A) as well as
down to calciﬁed layer (B) and down to but not through the subchondral
bone (C). Blisters are included in this grade (D)
ICRS grade 4—severely abnormal
Copyright © ICRS
Figure 2: The International Cartilage Repair Society (ICRS) Cartilage Lesion Classiﬁcation System. Reprinted with permission from the
ICRS Cartilage Injury Evaluation Package (http://www.cartilage.org/).
reported by several authors [14, 15, 37]. Weinstein et al. des-
cribed good results from arthroscopic debridement alone in
patientswithmildorminimalarthriticchangeandlessfavor-
able results in patients with more advanced changes (average
age 46, range 27–72 years old) [37]. Richards et al. combined
arthroscopic debridement with capsular release in young
patients (mean age 56 ± 12 years). This resulted in improved
glenohumeral motion and an average symptom free period
of 9 months in a small cohort of patients [15]. More recently,
Van Thiel et al. described a signiﬁcant decrease in pain in
55 of 71 patients, mean age 47 years old (range 18–77), after
arthroscopic glenohumeral debridement at a mean of 27
months postoperatively [14]. Although arthroscopic inter-
vention is not likely to halt arthritic progression, it may4 Advances in Orthopedics
(a) (b) (c)
Figure 3: Preoperative (a) Intraoperative (b), and postoperative (c) radiologic imaging of the Comprehensive Arthroscopic Management
procedure of an osteoarthritic shoulder of a 52-year-old male. (b) shows the osteoplasty of the inferior humeral osteophyte with the
arthroscopic burr.
provide a period of improved pain and function, thereby de-
laying a larger operation in those with physically demanding
occupations or recreational interests.
In some circumstances arthrosis of the glenohumeral
joint is accompanied by large inferior humeral osteophytes.
Previous authors have suggested that arthroscopic debride-
ment procedures are less eﬃcacious when osteophytes are
present [37]. It has also been shown in cadaveric studies that
the axillary nerve runs in close proximity to the inferior gle-
nohumeral capsule [38, 39] .T h e r e f o r e ,i tm a yb ep o s s i b l ef o r
a humeral osteophyte of suﬃcient size to compress the axil-
lary nerve and potentially result in posterior or lateral shoul-
der pain (axillary nerve distribution) similar to that experi-
enced with quadrilateral space syndrome. This may partially
explain less favorable results reported in this subset of pa-
tients if the axillary nerve is not properly decompressed.
Therefore, we have recently begun combining typical
arthroscopic debridement and capsular release, with a me-
ticulous humeral osteoplasty and an arthroscopic trans-ca-
psular axillary nerve decompression (CAM; Comprehensive
Arthroscopic Management) [22]. In our recently published
study, we reported on the results of 28 procedures in 27 pa-
tients [40]. All had severe glenohumeral osteoarthritis and
otherwise would have been candidates for total shoulder
arthroplasty. At an average of 20 months postoperatively, we
hadahighpatientsatisfactionrate,decreasedpain,improved
range of motion, and improved ASES scores. We had good
survivorshipaswell;onlyonepatienthadpersistentpainthat
was severe enough that he elected to undergo total shoulder
arthroplasty. Younger patients or those who place consid-
erable functional demands on the glenohumeral joint may
be excellent candidates for this type of procedure. Several of
the patients in this series are now many years out from their
CAM procedure and are still satisﬁed and highly functional.
For the appropriate patient, the addition of an axillary nerve
decompression and humeral osteoplasty may provide symp-
tomatic relief that is greater than simple debridement alone
(Figures 3(a)–3(c))[ 40]. These data suggest that the CAM
procedure may be a promising alternative for young and
active patients with early shoulder OA. In the future this
procedure may be able to be combined with other restorative
types of procedures, but further research is required.
3.3. Operative Treatment: Regeneration,
Repair, or Reconstruction
3.3.1. Microfracture. The technique of microfracture as a
marrow-stimulation procedure was ﬁrst described as a repair
option for full-thickness focal cartilage defect in the knee
with good clinical outcomes and low surgical morbidity
[41, 42]. Recently, this technique has also been increasingly
described successfully for focal defects of the glenohumeral
joint [17–19]. Millett et al. reported signiﬁcant improvement
atanaveragefollow-upof47monthsinpainscoresandfunc-
tional outcome in 81% of 31 cases in a population of grade
IV cartilage lesions (average age 43, range 19–59 years old).
The greatest improvements were noted in small lesions of the
humerus and the worst in patients with both humeral and
glenoid defects [17]. Frank et al. recently reported results of
17 cases at an average follow-up 27.8 months (average age
37, range 18–35 years old). They also reported signiﬁcant
improvements in pain and functional outcomes scores. The
average size of treated lesions was 5.07cm2 for humeral
lesions and 1.66cm2 for glenoid defects [18]. Finally, a small
study by Siebold et al. involving 5 patients with a mean age
of 32 and an age range of 16–56 years old also showed sig-
niﬁcant improvements in pain and functional outcomes sco-
res after performing a combination of microfracture and pe-
riosteal ﬂap for focal chondral lesions (Figures 4(a)-4(b))
[19].
3.3.2. Autologous Osteochondral Transfers. Similar to micro-
fracture, the technique of autologous osteochondral transfer
has been extensively studied and appears to be eﬀective
for treatment of full-thickness cartilage defects of the knee
[43, 44]. While microfracture is performed arthroscopically,
chondral transfers often require an open procedure andAdvances in Orthopedics 5
(a) (b)
Figure 4: Arthroscopic images of preparation for (a) and result of (b) microfracture technique of a 2 × 2cm glenoid lesion in a 65-year-old
male.
(a) (b) (c)
Figure 5: Large humeral head cartilage defect (a), excised (b) and replaced with an osteochondral allograft (c) in a patient younger than 50
years old.
also harbors the risk of donor site morbidity. By contrast
osteochondral transfers provide the advantage of facilitating
transfer of both cartilage and bone. Therefore it is capable
of treating bone defects in addition to full-thickness cartilage
lesions. Little is presently known regarding the results of this
procedureintheglenohumeraljoint.Scheibeletal.presented
a small case series of 8 grade IV lesions with 32 months of
follow-up; the average age of included patients was 43 years
old (range 23–57) [20]. Autograft osteochondral transfers
from the knee were performed, resulting in improved
shoulder outcome scores; however donor site morbidity of
the knee was reported to be 20%.
3.3.3. Autologous Chondrocyte Implantation (ACI). ACI tech-
niqueshavealsobeensuccessfulforthetreatmentofcartilage
lesions of the knee [45]. ACI provides the advantage of elim-
inating the risk of donor site morbidity, though it must be
performed as a staged approach using an open surgical tech-
nique. Young and active patients with high demand of
shoulder function and isolated focal lesions of the humeral
cartilage seem most ﬁt for this type of treatment. To date,
only one case report of a young baseball player has been pub-
lished reporting good results 12 months after surgery [21].
3.3.4.OsteochondralAllografts. OsteochondralAllograftscan
be used for large full-thickness cartilage lesions of the hu-
merus and also provide the advantage of avoiding donor-
site morbidity risk (Figures 5(a)–5(c)). However, possible
disadvantages include limited chondrocyte viability, loss of
matrixstructure,andtransmissionofdisease.Asarestorative
technique, allograft transfer has proven eﬃcacious in other
joints [46–48] but their application to the glenohumeral
joint is relatively uncommon. The most frequent use of al-
lograft in the glenohumeral joint is for the treatment of en-
gaging Hill-Sachs lesions and bony deﬁcits resulting from
glenohumeralinstabilityfollowingtumorresections[49,50].
Recently Krishnan et al. published promising early results in
4 patients, mean age 47, of an all-arthroscopic technique for6 Advances in Orthopedics
(a) (b) (c)
Figure 6: Preparation of the glenoid (a) for soft-tissue (b) resurfacing of the glenoid in a patient younger than 50 years old with a glenoid
cartilage defect (c).
osteochondral allograft resurfacing of both the glenoid and
humeral articular surface [51]. Though possibly a promising
alternative for young and active patients with early shoulder
OA, further research and follow-up is required.
3.3.5.BiologicResurfacing/InterpositionArthroplasty. Though
still primarily investigational, treatment of focal chondral
defects of the glenoid using biologic glenoid resurfacing was
ﬁrst described in the late 1980s [52]. Since then several
diﬀerent techniques have been described [53, 54].
Nicholson et al. conducted a prospective study in which
36 patients, average age 51 and range 30–75 years old, were
treated with humeral hemiarthroplasty combined with ante-
rior capsular interposition in 7 shoulders, autogenous fascia
lata in 11 patients, and Achilles tendon allograft in the re-
maining 18 shoulders [52]. The authors report pain relief
comparable to those of total shoulder arthroplasty. Ball et al.
reported similar favorable results at two-year follow-up after
treating 6 patients, average age 48 years old (range 33–54),
withfascialataandanteriorcapsuleglenoidresurfacingtech-
niques [55].
Otherauthorsreportedonopen[56]andlaterarthrosco-
pic [57] glenoid resurfacing techniques using lateral menis-
cus allografts. A cadaveric study by Pennington and Bartz
showed that lateral meniscus allograft signiﬁcantly reduced
contact forces as compared to the medial meniscus [56].
Huijsmansetal.reportedoverallgoodresultswithaconside-
rable complication rate using lateral meniscus allografts to
resurface 30 glenoids of young patients (mean age 42 and ra-
nge 18–52) with glenohumeral OA in combination with hu-
meral hemiarthroplasty [53].
Elhassan et al. described an arthroscopic technique of
glenoid resurfacing using a GraftJacket (Wright Medical
Technology, Arlington, TN, USA), consisting of processed
human donor skin [58]. Promising preliminary results using
GraftJacket interposition have been reported at 6-months
follow-up in 6 patients [54].
Though many of these techniques have shown some
promising early results in terms of pain relief, most recently
Gobezie et al. published devastating results of 13 patients,
mean age 34 and range 18–49, treated with soft-tissue re-
surfacing of the glenoid alongside arthroplasty of the hu-
meral head [59]. Revision total shoulder arthroplasty was
required by 77% of patients at a mean of 14 months post-
operatively because of persistent pain and decreased range of
motion. The authors concluded that this procedure is not a
reliablemethodoftreatmentinyoungpatientswithshoulder
OA based on both the poor clinical outcome and absence of
the graft acting as a durable glenoid surface (Figures 6(a)–
6(c)).
4. Conclusions
Themanagementofosteochondralpathologyoftheshoulder
in young active patients is a challenge, and the optimal treat-
ment has yet to be completely established. If nonoperative
treatment fails, several restorative and palliative surgical
techniques are currently optional. Historically, joint debride-
ment has shown good results, and a combination of arthro-
scopic debridement with a capsular release, humeral osteo-
plasty,andtranscapsularaxillarynervedecompressionseems
to be a promising procedural advance, particularly when
large humeral osteophytes are present.
Currently, microfracture seems the most eﬀective repar-
ative treatment modality available for focal cartilage lesions.
Though several other techniques have been described, such
as autologous chondrocyte implantation, autologous osteo-
chondral transfers, osteochondral allografts, and biologic
soft tissue interposition arthroplasties, they are currently
mainly still investigational procedures. Long-term results
and documentation of the natural history of disease follow-
ing these procedures are required to optimize joint-preser-
vation treatment.
Acknowledgments
The authors acknowledge the International Cartilage Repair
Society for granting permission to republish the ICRS Clas-
siﬁcation of Cartilage Injury. This work was not supported
directly by an outside funding or grant. However, one orAdvances in Orthopedics 7
more of the authors, P. J. Millett, M.D., M.S., and O. A. van
der Meijden, M.D., have received from a commercial entity
something of value (exceeding the equivalent of US$500) not
relatedtothispaperorresearchfromArthrex.P.J.Millettisa
consultantandreceivespaymentsfromArthrexandhasstock
options in Game Ready. In addition, O. A. van der Meijden’s
research intern salary was supported by Arthrex. This pa-
per was supported by The Steadman Philippon Research In-
stitutewhichisa501(c)3nonproﬁtinstitutionsupportedﬁn-
ancially by private donations and corporate support from
the following entities: Smith & Nephew Endoscopy, Arthrex,
Arthrocare,Siemens,OrthoRehab,andOssurAmericas.This
research was performed at the Steadman Philippon Research
Institute in Vail, CO, USA.
References
[ 1 ]J .M .H o o t m a n ,M .W .B r a u l t ,C .G .H e l m i c k ,K .A .T h e i s ,
and B. S. Armour, “Prevalence and most common causes of
disability among adults—United States, 2005,” MMWR: Mor-
bidity and Mortality Weekly Report, vol. 58, no. 16, pp. 421–
426, 2009.
[ 2 ]Y .J .C h e n g ,J .M .H o o t m a n ,L .B .M u r p h y ,G .A .L a n g m a i d ,
and C. G. Helmick, “Prevalence of doctor-diagnosed arthritis
and arthritis-attributable activity limitation—United States
2007–2009,” MMWR: Morbidity and Mortality Weekly Report,
vol. 59, no. 39, pp. 1261–1265, 2010.
[3] American Academy of Orthopaedic Surgeons, Burden of Mus-
culoskeletal Diseases in the United States: Prevalence, Societal
and Economic Cost, American Academy of Orthopaedic Sur-
geons, Rosemont, Ill, USA, 2008.
[4] R. Izquierdo, I. Voloshin, S. Edwards et al., “Treatment of
glenohumeralosteoarthritis,”JournaloftheAmericanAcademy
of Orthopaedic Surgeons, vol. 18, no. 6, pp. 375–382, 2010.
[5] R. M. Orfaly, C. A. Rockwood Jr., C. Z. Esenyel, and M. A.
Wirth, “A prospective functional outcome study of shoulder
arthroplasty for osteoarthritis with an intact rotator cuﬀ,”
Journal of Shoulder and Elbow Surgery, vol. 12, no. 3, pp. 214–
221, 2003.
[6] P. Raiss, P. R. Aldinger, P. Kasten, M. Rickert, and M. Loew,
“Total shoulder replacement in young and middle-aged pa-
tients with glenohumeral osteoarthritis,” Journal of Bone and
Joint Surgery B, vol. 90, no. 6, pp. 764–769, 2008.
[7] J. P. Iannotti and T. R. Norris, “Inﬂuence of preoperative fac-
tors on outcome of shoulder arthroplasty for glenohumeral
osteoarthritis,” Journal of Bone and Joint Surgery A, vol. 85, no.
2, pp. 251–258, 2003.
[8] G. M. Gartsman, T. S. Roddey, and S. M. Hammerman,
“Shoulder arthroplasty with or without resurfacing of the gle-
noid in patients who have osteoarthritis,” Journal of Bone and
Joint Surgery A, vol. 82, no. 1, pp. 26–34, 2000.
[ 9 ]R .S .B o o r m a n ,B .K o p j a r ,E .F e h r i n g e r ,R .S .C h u r c h i l l ,K .
Smith, and F. A. Matsen III, “The eﬀect of total shoulder ar-
throplasty on self-assessed health status is comparable to that
of total hip arthroplasty and coronary artery bypass grafting,”
Journal of Shoulder and Elbow Surgery, vol. 12, no. 2, pp. 158–
163, 2003.
[10] E.V.Fehringer,B.Kopjar,R.S.Boorman,R.S.Churchill,K.L.
Smith, and F. A. Matsen III, “Characterizing the functional
improvement after total shoulder arthroplasty for osteoarthri-
tis,” Journal of Bone and Joint Surgery A,v o l .8 4 ,n o .8 ,p p .
1349–1353, 2002.
[11] M. A. Wirth, R. S. Tapscott, C. Southworth, and C. A. Rock-
wood Jr., “Treatment of glenohumeral arthritis with a hemi-
arthroplasty: a minimum ﬁve-year follow-up outcome study,”
Journal of Bone and Joint Surgery A,vol. 88, no. 5, pp. 964–973,
2006.
[12] K. J. Boselli, C. S. Ahmad, and W. N. Levine, “Treatment of
glenohumeral arthrosis,” American Journal of Sports Medicine,
vol. 38, no. 12, pp. 2558–2572, 2010.
[13] J. W. Sperling, S. A. Antuna, J. Sanchez-Sotelo, C. Schleck,
and R. H. Coﬁeld, “Shoulder arthroplasty for arthritis after
instability surgery,” Journal of Bone and Joint Surgery A, vol.
84, no. 10, pp. 1775–1781, 2002.
[14] G. S. Van Thiel, S. Sheehan, R. M. Frank et al., “Retrospective
analysis of arthroscopic management of glenohumeral degen-
erative disease,” Arthroscopy, vol. 26, no. 11, pp. 1451–1455,
2010.
[15] D. P. Richards and S. S. Burkhart, “Arthroscopic debridement
and capsular release for glenohumeral osteoarthritis,” Arthro-
scopy, vol. 23, no. 9, pp. 1019–1022, 2007.
[16] B. J. Kerr and E. C. McCarty, “Outcome of arthroscopic de-
bridement is worse for patients with glenohumeral arthritis of
both sides of the joint,” Clinical Orthopaedics and Related Re-
search, vol. 466, no. 3, pp. 634–638, 2008.
[17] P. J. Millett, B. H. Huﬀard, M. P. Horan, R. J. Hawkins, and
J. R. Steadman, “Outcomes of full-thickness articular cartilage
injuries of the shoulder treated with microfracture,” Arthro-
scopy, vol. 25, no. 8, pp. 856–863, 2009.
[18] R. M. Frank, G. S. Van Thiel, M. A. Slabaugh, A. A. Romeo,
B. J. Cole, and N. N. Verma, “Clinical outcomes after micro-
fracture of the glenohumeral joint,” The American Journal of
Sports Medicine, vol. 38, no. 4, pp. 772–781, 2010.
[19] R. Siebold, S. Lichtenberg, and P. Habermeyer, “Combination
of microfracture and periostal-ﬂap for the treatment of focal
full thickness articular cartilage lesions of the shoulder: a
prospective study,” Knee Surgery, Sports Traumatology, Arthro-
scopy, vol. 11, no. 3, pp. 183–189, 2003.
[20] M. Scheibel, C. Bartl, P. Magosch, S. Lichtenberg, and P.
Habermeyer, “Osteochondral autologous transplantation for
the treatment of full-thickness articular cartilage defects of the
shoulder,” Journal of Bone and Joint Surgery B,v o l .8 6 ,n o .7 ,
pp. 991–997, 2004.
[21] A. A. Romeo, B. J. Cole, A. D. Mazzocca, J. A. Fox, K. B. Free-
man, and E. Joy, “Autologous chondrocyte repair of an arti-
cular defect in the humeral head,” Arthroscopy, vol. 18, no. 8,
pp. 925–929, 2002.
[22] P.J.Millett,M.P.Horan,andF.Elser,“Comprehensivearthro-
scopic management (CAM) of shoulder osteoarthritis in
young active patients,” in Proceedings of the 29th Annual
Meeting (AANA ’10), Hollywood, Fla, USA, May 2010.
[23] J. A. Fox, B. J. Cole, A. A. Romeo et al., “Articular cartilage
thickness of the humeral head: an anatomic study,” Orthope-
dics, vol. 31, no. 3, p. 216, 2008.
[24] L. J. Soslowsky, E. L. Flatow, L. U. Bigliani, and V. C. Mow,
“Articular geometry of the glenohumeral joint,” Clinical
OrthopaedicsandRelatedResearch,no.285,pp.181–190,1992.
[25] L. P. McCarty III and B. J. Cole, “Nonarthroplasty treatment
of glenohumeral cartilage lesions,” Arthroscopy,v o l .2 1 ,n o .9 ,
pp. 1131–1142, 2005.
[26] N. P. Cohen, R. J. Foster, and V. C. Mow, “Composition and
dynamics of articular cartilage: structure, function, and main-
taining healthy state,” Journal of Orthopaedic and Sports
Physical Therapy, vol. 28, no. 4, pp. 203–215, 1998.8 Advances in Orthopedics
[27] R. E. Outerbridge, “The etiology of chondromalacia patellae,”
Clinical Orthopaedics and Related Research,v o l .4 3 ,n o .4 ,p p .
752–757, 1961.
[28] M. Brittberg and C. S. Winalski, “Evaluation of cartilage in-
juries and repair,” Journal of Bone and Joint Surgery A, vol. 85,
no. 1, pp. 58–69, 2003.
[ 2 9 ]H .E l l m a n ,E .H a r r i s ,a n dS .P .K a y ,“ E a r l yd e g e n e r a t i v ej o i n t
diseasesimulatingimpingementsyndrome:arthroscopicﬁnd-
ings,” Arthroscopy, vol. 8, no. 4, pp. 482–487, 1992.
[30] G. M. Gartsman and E. Taverna, “The incidence of glenohu-
meral joint abnormalities associated with full- thickness, re-
parable rotator cuﬀ tears,” Arthroscopy, vol. 13, no. 4, pp. 450–
455, 1997.
[ 3 1 ]K .J .P a l e y ,F .W .J o b e ,M .M .P i n k ,R .S .K v i t n e ,a n dN .S .
ElAttrache, “Arthroscopic ﬁndings in the overhand throwing
athlete: evidence for posterior internal impingement of the
rotator cuﬀ,” Arthroscopy, vol. 16, no. 1, pp. 35–40, 2000.
[32] D.V.Guntern,C.W.A.Pﬁrrmann,M.R.Schmidetal.,“Artic-
ular cartilage lesions of the glenohumeral joint: diagnostic ef-
fectiveness of MR arthrography and prevalence in patients
with subacromial impingement syndrome,” Radiology, vol.
226, no. 1, pp. 165–170, 2003.
[33] F. Elser, S. Braun, C. B. Dewing, and P. J. Millett, “Glenohu-
meral joint preservation: current options for managing artic-
ular cartilage lesions in young, active patients,” Arthroscopy,
vol. 26, no. 5, pp. 685–696, 2010.
[34] W. Zhang, A. Jones, and M. Doherty, “Does paracetamol (ac-
etaminophen) reduce the pain of osteoarthritis? A meta-an-
alysisofrandomisedcontrolledtrials,”AnnalsoftheRheumatic
Diseases, vol. 63, no. 8, pp. 901–907, 2004.
[35] T. Pincus, G. Koch, H. Lei et al., “Patient Preference for Place-
bo, Acetaminophen (paracetamol) or Celecoxib Eﬃcacy Stud-
ies (PACES): two randomised, double blind, placedo control-
led, crossover clinical trials in patients with knee or hip osteo-
arthritis,” Annals of the Rheumatic Diseases,v o l .6 3 ,n o .8 ,p p .
931–939, 2004.
[36] E. Silverstein, R. Leger, and K. P. Shea, “The use of intra-
articular hylan G-F 20 in the treatment of symptomatic
osteoarthritis of the shoulder: a preliminary study,” American
Journal of Sports Medicine, vol. 35, no. 6, pp. 979–985, 2007.
[37] D.M.Weinstein,J.S.Bucchieri,R.G.Pollock,E.L.Flatow,and
L. U. Bigliani, “Arthroscopic debridement of the shoulder for
osteoarthritis,” Arthroscopy, vol. 16, no. 5, pp. 471–476, 2000.
[38] M. R. Price, E. D. Tillett, R. D. Acland, and G. S. Nettleton,
“Determining the relationship of the axillary nerve to the
shoulderjointcapsulefromanarthroscopicperspective,”Jour-
nal of Bone and Joint Surgery A, vol. 86, no. 10, pp. 2135–2142,
2004.
[39] C. M. Ball, T. Steger, L. M. Galatz, and K. Yamaguchi, “The
posterior branch of the axillary nerve: an anatomic study,”
Journal of Bone and Joint Surgery A, vol. 85, no. 8, pp. 1497–
1501, 2003.
[40] P. J. Millett and T. R. Gaskill, “Arthroscopic management of
glenohumeral arthrosis: humeral osteoplasty, capsular release,
and arthroscopic axillary nerve release as a joint-preserving
approach,” Arthroscopy, vol. 27, no. 9, pp. 1296–1303, 2011.
[41] J. R. Steadman, W. G. Rodkey, S. B. Singleton, and K. K.
Briggs, “Microfracture technique for full-thickness chondral
defects: technique and clinical results,” Operative Techniques
in Orthopaedics, vol. 7, no. 4, pp. 300–304, 1997.
[42] J. R. Steadman, K. K. Briggs, J. J. Rodrigo, M. S. Kocher, T. J.
Gill, and W. G. Rodkey, “Outcomes of microfracture for trau-
maticchondraldefectsoftheknee:average11-yearfollow-up,”
Arthroscopy, vol. 19, no. 5, pp. 477–484, 2003.
[43] L. Hangody and P. Fules, “Autologous osteochondral mosaic-
plasty for the treatment of full-thickness defects of weight-
bearing joints: ten years of experimental and clinical experi-
ence,” Journal of Bone and Joint Surgery A, vol. 85, supplement
2, no. 1, pp. 25–32, 2003.
[44] G. Bentley, L. C. Biant, R. W. J. Carrington et al., “A pro-
spective, randomised comparison of autologous chondrocyte
implantation versus mosaicplasty for osteochondral defects in
the knee,” Journal of Bone and Joint Surgery B,v o l .8 5 ,n o .2 ,
pp. 223–230, 2003.
[ 4 5 ]L .P e t e r s o n ,M .B r i t t b e r g ,I .K i v i r a n t a ,E .L .˚ Akerlund, and
A. Lindahl, “Autologous chondrocyte transplantation: biome-
chanics and long-term durability,” American Journal of Sports
Medicine, vol. 30, no. 1, pp. 2–12, 2002.
[46] A. E. Gross, W. Kim, F. Las Heras, D. Backstein, O. Saﬁr, and
K. P. H. Pritzker, “Fresh osteochondral allografts for posttrau-
m a ti ck n eed e f ect s :l o n g - t e rmf o ll o w u p , ”ClinicalOrthopaedics
and Related Research, vol. 466, no. 8, pp. 1863–1870, 2008.
[ 4 7 ]A .G .P .M c D e r m o t t ,F .L a n g e r ,K .P .H .P r i t z k e r ,a n dA .E .
Gross, “Fresh small-fragment osteochondral allografts. Long-
term follow-up study on ﬁrst 100 cases,” Clinical Orthopaedics
and Related Research, vol. 197, pp. 96–102, 1985.
[48] M. T. Ghazavi, K. P. Pritzker, A. M. Davis, and A. E. Gross,
“Freshosteochondralallograftsforpost-traumaticosteochon-
dral defects of the knee,” Journal of Bone and Joint Surgery B,
vol. 79, no. 6, pp. 1008–1013, 1997.
[49] F.ChapovskyandJ.D.KellyIV,“Osteochondralallografttran-
splantation for treatment of glenohumeral instability,”
Arthroscopy, vol. 21, no. 8, p. 1007, 2005.
[50] H. de Groot, D. Donati, M. D. di Liddo, E. Gozzi, and M. Mer-
curi, “The use of cement in osteoarticular allografts for prox-
imal humeral bone tumors,” Clinical Orthopaedics and Related
Research, no. 427, pp. 190–197, 2004.
[51] S. G. Krishnan, R. J. Nowinski, D. Harrison, and W. Z. Burk-
head, “Humeral hemiarthroplasty with biologic resurfacing of
theglenoidforglenohumeralarthritis:twotoﬁfteen-yearout-
comes,” Journal of Bone and Joint Surgery A,v o l .8 9 ,n o .4 ,p p .
727–734, 2007.
[52] G. P. Nicholson, J. L. Goldstein, A. A. Romeo et al., “Lateral
meniscusallograftbiologicglenoidarthroplastyintotalshoul-
der arthroplasty for young shoulders with degenerative joint
disease,” Journal of Shoulder and Elbow Surgery,v o l .1 6 ,n o .5 ,
pp. S261–S266, 2007.
[53] P.Huijsmans,C.Roberts,K.vanRooyen,D.F.duToit,andJ.F.
deBeer,“ThetreatmentofglenohumeralOAintheyoungand
active patient with the Graft Jacket: preliminary results,” Jour-
nal of Bone and Joint Surgery, vol. 87, supplement 3, p. 275,
2004.
[54] W. Z. Burkhead Jr. and K. S. Hutton, “Biologic resurfacing of
the glenoid with hemiarthroplasty of the shoulder,” Journal of
Shoulder and Elbow Surgery, vol. 4, no. 4, pp. 263–270, 1995.
[55] C.M.Ball,L.M.Galatz,andK.Yamaguchi,“Meniscalallograft
interposition arthroplasty for the arthritic shoulder: descrip-
tion of a new surgical technique,” Techniques in Shoulder &
Elbow Surgery, vol. 2, no. 4, pp. 247–254, 2001.
[56] W. T. Pennington and B. A. Bartz, “Arthroscopic glenoid re-
surfacingwithmeniscalallograft:aminimallyinvasivealterna-
tive for treating glenohumeral arthritis,” Arthroscopy, vol. 21,
no. 12, pp. 1517–1520, 2005.
[ 5 7 ] R .A .C r e i g h t o n ,B .J .C o l e ,G .P .N i c h o l s o n ,A .A .R o m e o ,a n d
E. P. Lorenz, “Eﬀect of lateral meniscus allograft on shoulder
articular contact areas and pressures,” Journal of Shoulder and
Elbow Surgery, vol. 16, no. 3, pp. 367–372, 2007.Advances in Orthopedics 9
[58] B. Elhassan, M. Ozbaydar, D. Diller, L. D. Higgins, and J. J.
P. Warner, “Soft-tissue resurfacing of the glenoid in the treat-
ment of glenohumeral arthritis in active patients less than ﬁfty
years old,” Journal of Bone and Joint Surgery A,v o l .9 1 ,n o .2 ,
pp. 419–424, 2009.
[ 5 9 ]R .G o b e z i e ,C .J .L e n a r z ,J .P .W a n n e r ,a n dJ .J .S t r e i t ,“ A l l -
arthroscopic biologic total shoulder resurfacing,” Arthroscopy,
vol. 27, no. 11, pp. 1588–1593, 2011.